Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTG Therapeutics Inc

TG Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
56.4519 USD -3.37 ( 5.64%)
Last update at 2026-11-09T17:47:00Z
VOLUME
1786781
Market Cap
8118.78M
P/E
19.72

Momentum Score

…

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
54.60
Low
58.99
High
52 Week Price Range
26.76
Low
59.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

TG Therapeutics is a biopharmaceutical company developing B‑cell targeted therapies for hematologic cancers and autoimmune disorders, centered on anti‑CD20 antibodies and PI3K inhibitors. Long-term growth drivers include advancement of pivotal trials, regulatory approvals and label expansions, strategic partnerships, and successful commercialization, which may benefit investors if programs reach market.
Key risks are clinical or regulatory failures, safety or efficacy issues in late‑stage studies, intense competition from larger peers, and ongoing financing or execution risk that could delay or dilute value.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
59.83
Dividend Yield
-
Revenue TTM
799.54M
Revenue Per Share
5.61
Gross Profit TTM
658.60M
Debt / Equity
0.40
ROE
100.28%
Net Debt
181.58M
ROCE
14.75%
Diluted EPS TTM
2.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 107.39M 25.59M 13.06M -198.34M -348.10M
Net income 447.18M 23.38M 12.67M -203.83M -355.55M
Selling general administrative 232.03M 154.30M 122.71M 83.23M 152.14M
Selling and marketing expenses - - 13.43M 64.05M -
Gross profit 515.57M 290.52M 219.53M 2.52M 5.90M
Reconciled depreciation 0.24M 0.28M 0.42M 0.52M 0.28M
Ebit 134.12M 49.62M 25.68M -192.84M -344.77M
Ebitda 134.36M 49.90M 26.10M -188.14M -342.46M
Depreciation and amortization 0.24M 0.28M 0.42M 4.70M 2.31M
Non operating income net other - - - - 2.31M
Operating income 123.32M 41.93M 20.63M -192.84M -344.77M
Other operating expenses 492.96M 287.07M 213.03M 195.62M 351.46M
Interest expense 26.73M 24.03M 12.62M 10.19M 5.64M
Tax provision -339.79M 2.21M 0.39M - -
Net interest income -26.73M -24.03M -12.62M -10.19M -5.64M
Income tax expense -339.79M 2.21M 0.39M 5.50M 7.45M
Total revenue 616.29M 329.00M 233.66M 2.79M 6.69M
Total operating expenses 392.25M 248.59M 198.90M 195.36M 350.67M
Cost of revenue 100.71M 38.49M 14.13M 0.27M 0.79M
Total other income expense net -15.93M -16.34M -7.57M -5.50M -3.33M
Net income from continuing ops 447.18M 23.38M 12.67M -182.65M -348.10M
Net income applicable to common shares - - - -182.65M -348.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1063.25M 577.69M 329.59M 193.57M 379.63M
Other current assets 57.58M 15.72M 9.52M 6.60M 2.88M
Total liab 415.23M 355.33M 169.09M 134.99M 142.48M
Total stockholder equity 648.02M 222.36M 160.50M -1527.03M -1328.70M
Deferred long term liab - - - 0.30M 0.46M
Other current liab 23.97M 78.11M 13.50M 9.30M 62.97M
Common stock 0.16M 0.16M 0.15M 0.15M 0.14M
Capital stock 0.16M 0.16M 0.15M 0.15M 0.14M
Retained earnings -1082.02M -1529.19M -1514.36M -1527.03M -1328.70M
Other liab - - - 0.30M 0.46M
Good will - 0.80M 0.80M 0.80M 0.80M
Other assets - - 329.59M 2.90M 3.10M
Cash 79.15M 179.89M 92.93M 102.30M 298.89M
Total current liabilities 153.76M 90.68M 53.72M 53.20M 65.38M
Current deferred revenue 21.23M 11.41M 0.30M 0.30M 0.46M
Net debt 181.58M 73.83M 17.86M -19.24M -219.84M
Short term debt 1.04M 1.16M 1.45M 1.58M 2.41M
Short long term debt - - - - 0.97M
Short long term debt total 260.73M 253.72M 110.80M 83.06M 79.05M
Other stockholder equity 1729.88M 1751.40M 1674.71M -0.15M -0.14M
Property plant equipment - - - 0.31M 0.60M
Total current assets 630.76M 566.36M 317.94M 168.27M 330.96M
Long term investments 74.83M 0.81M 0.00M 12.40M 35.53M
Net tangible assets - - - 57.79M 310.72M
Short term investments 62.82M 131.11M 124.58M 59.37M 15.88M
Net receivables 305.63M 129.19M 51.09M 0.00M 1.39M
Long term debt 245.65M 244.43M 100.12M 71.14M 66.79M
Inventory 125.59M 110.46M 39.82M - -23.60M
Accounts payable 107.51M 58.30M 38.47M 42.02M -0.46M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - 0.15M 0.14M
Retained earnings total equity - - - -1527.03M -1328.70M
Treasury stock - - - - -0.23M
Non currrent assets other 19.07M 3.37M 1.42M 1.27M 1.26M
Non current assets total 432.49M 11.33M 11.64M 25.30M 48.66M
Capital lease obligations 8.06M 9.29M 10.68M 11.93M 11.28M
Long term debt total - - - 71.14M 66.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.01M -1.04M -50.65M -20.01M 0.07M
Change to liabilities - - - -11.22M -2.32M
Total cashflows from investing activities 13.80M -1.04M -50.65M -20.01M -0.33M
Net borrowings 0.00M 137.26M 25.00M -0.97M 38.98M
Total cash from financing activities -89.73M 128.53M 72.70M -0.39M 41.42M
Change to operating activities - - - 8.13M -26.67M
Net income 447.18M 23.38M 12.67M -198.34M -348.10M
Change in cash -100.70M 86.97M -9.36M -196.57M -254.55M
Begin period cash flow 181.19M 94.22M 103.58M 300.15M 554.70M
End period cash flow 80.49M 181.19M 94.22M 103.58M 300.15M
Total cash from operating activities -24.77M -40.52M -31.41M -176.17M -295.63M
Issuance of capital stock 0.00M 0.00M 46.30M 0.00M 2.22M
Depreciation 0.06M 0.28M 0.42M 0.52M 0.49M
Other cashflows from investing activities 14.01M -0.99M - -20.00M 0.07M
Dividends paid - - - - 0.00M
Change to inventory -33.45M -66.85M -36.94M - -
Change to account receivables -176.44M -78.09M -51.09M 1.39M -1.39M
Sale purchase of stock -91.24M -8.76M 0.00M 0.58M 2.44M
Other cashflows from financing activities -89.73M 0.03M 1.41M 0.58M 69.20M
Change to netincome - - - 19.07M 60.70M
Capital expenditures 0.21M 0.04M 0.00M 0.01M 0.40M
Change receivables - - - 1.39M -1.39M
Cash flows other operating - - - 10.90M -6.61M
Cash and cash equivalents changes - - - -196.57M -254.55M
Change in working capital -194.54M -109.30M -84.66M -1.65M -12.22M
Stock based compensation 64.67M 42.54M 37.93M 19.18M 61.27M
Other non cash items 5.86M 2.58M 2.22M 4.11M 2.40M
Free cash flow -24.99M -40.56M -31.41M -176.18M -296.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TGTX
TG Therapeutics Inc		 -3.37
5.64%		 56.45 19.72 25.00 10.15 13.68 10.59 60.75
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560

212 554 4484

https://www.tgtherapeutics.com

399

Name Title Year Born
Mr. Michael S. Weiss Esq. Chairman, CEO & Pres 1966
Mr. Sean A. Power CPA, CPA CFO, Corp. Sec. & Treasurer 1982
Jenna Bosco Sr. VP of Corp. Communications NA
Mr. Adam Waldman Chief Commercialization Officer NA
Mr. Michael S. Weiss Esq. Chairman, CEO & President 1966
Mr. Sean A. Power CPA CFO, Corporate Secretary & Treasurer 1982
Jenna Bosco Senior Vice President of Corporate Communications NA
Mr. Michael S. Weiss Esq., J.D. Chairman, CEO & President 1966
Ms. Jenna Bosco Senior Vice President of Corporate Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…